Literature DB >> 12816535

Hypertensive response to chronic NG-nitro-L-arginine methyl ester (L-NAME) treatment is similar in immature and adult Wistar rats.

Josef Zicha1, Olga Pechánová, Zdena Dobesová, Jaroslav Kunes.   

Abstract

The aim of our study was to evaluate whether the blood pressure (BP) response to chronic inhibition of NO synthase (NOS) is exaggerated in young rats, which were reported to develop a more pronounced salt hypertension than the adult ones. The enhanced BP rise in immature rats subjected to excess salt intake might be due either to a generally increased reactivity in immature organisms to these stimuli or to a greater impairment of NO bioavailability that accompanies the development of salt hypertension. To determine between the two alternatives, we have compared the hypertensive response and the extent of NOS inhibition in immature (4-week-old) and adult (12-week-old) male Wistar rats which were treated with NG-nitro-L-arginine methyl ester (L-NAME, 40 mg/kg of body mass per day) for 4 weeks. BP and NOS activity in the aorta, left ventricle and kidney were determined at the end of the experiment. It should be noted that chronic L-NAME treatment caused a similar degree of NOS inhibition in both age groups (irrespective of tissue examined). There was no significant difference in BP elevation between young and adult animals chronically treated with L-NAME. A strong negative correlation between NOS activity and BP level was observed in separate groups of normotensive controls and L-NAME hypertensive rats. Thus the BP of both normotensive and hypertensive animals seems to be inversely proportional to the production of NO. It can be concluded that there was the same BP rise in both age groups of L-NAME-treated rats in which a similar degree of NOS inhibition was disclosed. This suggests that the altered NO bioavailability (but not the generally exaggerated reactivity to hypertensive stimuli) is the cause of exaggerated hypertensive response observed in immature rats exposed to excess salt intake.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12816535     DOI: 10.1042/CS20030078

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  4 in total

1.  Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability.

Authors:  Graham R Lawton; Hantamalala Ralay Ranaivo; Laura K Chico; Haitao Ji; Fengtian Xue; Pavel Martásek; Linda J Roman; D Martin Watterson; Richard B Silverman
Journal:  Bioorg Med Chem       Date:  2009-02-14       Impact factor: 3.641

2.  Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy.

Authors:  Haitao Ji; Sidhartha Tan; Jotaro Igarashi; Huiying Li; Matthew Derrick; Pavel Martásek; Linda J Roman; Jeannette Vásquez-Vivar; Thomas L Poulos; Richard B Silverman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

3.  Synthesis and enzymatic evaluation of 2- and 4-aminothiazole-based inhibitors of neuronal nitric oxide synthase.

Authors:  Graham R Lawton; Haitao Ji; Pavel Martásek; Linda J Roman; Richard B Silverman
Journal:  Beilstein J Org Chem       Date:  2009-06-04       Impact factor: 2.883

4.  Insights into the structural determinants for selective inhibition of nitric oxide synthase isoforms.

Authors:  Bruno L Oliveira; Irina S Moreira; Pedro A Fernandes; Maria J Ramos; Isabel Santos; João D G Correia
Journal:  J Mol Model       Date:  2012-12-21       Impact factor: 1.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.